# US 2004/0072879 A1 · Crystalline 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-3-ethoxycarbonyl-5-methoxycarbonyl-6-methyl-1,4-dihydropyridine maleate salt (Amlodipine)

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0072879 A1
- Document ID: US20040072879A1
- Status: Published application
- Kind: A1
- Application number: 10/269,095
- Filed: 2002-10-10
- Published: 2004-04-15
- Earliest claimed: 2002-10-10
- Assignees: Dr. Reddy's Laboratories, Inc.
- Inventors: Sajja Eswaraiah; Ganta Madhusudan Reddy; Jambula Mukunda Reddy; Kammili Venkata Rambabu; Bolugoddu Vijaya Bhaskar
- Web page: https://patentgrep.com/patent/US20040072879A1

## CPC

- C07D 211/90: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to novel crystalline forms of Amlodipine Maleate These crystalline forms are useful as pharmaceutical agents. This invention also relates to pharmaceutical compositions which include these crystalline forms and to methods of treatment using these crystalline forms. The novel crystalline compounds of the present invention are useful as calcium channel blockers and are thus useful as anti-ischaemic and anti-hypertensive agents.

## Claims

### Claim 1

Novel Crystalline Form I of Amlodipine Maleate.

### Claim 2

Form I of Amlodipine maleate characterized by an X-ray powder diffraction pattern with 2θ values at about 4.459, 8.871, 10.593, 11.160, 11.488, 12.700, 13.296, 13.590, 15.694, 17.730, 18.156, 18.608, 19.208, 19.772, 20.126, 20.908, 21.523, 21.964, 22.985, 23.687, 24.584, 25.085, 25.538, 26.269, 26.753, 27.504, 28.095, 29.972, 30.433, 31.175, 31.824, 32.671, 33.564, 34.132, 36.223, 37.836, 38.776, 39.914.

### Claim 3 (depends on 1)

Form I of Amlodipine maleate according to claim 1, characterized by XRD pattern substantially in accordance with FIG. 1.

### Claim 4 (depends on 2)

Form I of Amlodipine maleate according to claim 2, characterized by XRD pattern substantially in accordance with FIG. 1.

### Claim 5 (depends on 1)

Form I of Amlodipine maleate according to claim 1, characterized by DSC pattern having endo-endo peaks at about 174.1 and 176.6° C.

### Claim 6 (depends on 2)

Form I of Amlodipine maleate according to claim 2, characterized by DSC pattern having endo-endo peaks at about 174.1 and 176.6° C.

### Claim 7 (depends on 4)

Form I of Amlodipine maleate according to claim 4 characterized by DSC pattern substantially in accordance with FIG. 2.

### Claim 8

Novel Crystalline Form II of Amlodipine Maleate.

### Claim 9

Form II of Amlodipine maleate characterized by an X-ray powder diffraction pattern with 2θ values at about 4.421, 8.851, 10.147, 11.421, 12.032, 12.644, 13.071, 13.297, 13.490, 14.435, 14.838, 15.655, 17.052, 17.561, 18.072, 18.611, 19.186, 19.692, 20.078, 21.237, 21.958, 22.912, 23.536, 24.191, 24.493, 25.058, 25.932, 26.264, 26.717, 27.250, 28.051, 29.778, 31.728, 33.512, 33.987, 35.233, 37.085, 40.536.

### Claim 10 (depends on 8)

Form II of Amlodipine maleate according to claim 8, characterized by XRD pattern substantially in accordance with FIG. 3.

### Claim 11 (depends on 9)

Form II of Amlodipine maleate according to claim 9, characterized by XRD pattern substantially in accordance with FIG. 3.

### Claim 12 (depends on 8)

Form II of Amlodipine maleate according to claim 8, characterized by DSC pattern having endo-endo peaks at about 170.2, 173.6 and 175.1° C.

### Claim 13 (depends on 9)

Form II of Amlodipine maleate according to claim 9, characterized by DSC pattern having endo-endo peaks at about 170.2, 173.6 and 175.1° C.

### Claim 14 (depends on 13)

Form II of Amlodipine maleate according to claim 13, characterized by DSC pattern substantially in accordance with FIG. 4.

### Claim 15

A process for the preparation of Form I of Amlodipine maleate, which comprises the steps of:
a) dissolving maleic acid in a solvent or a mixture of solvents followed by addition of Amlodipine base;
b) maintaining the reaction mixture of step a), at a temperature ranging from ambient to the reflux temperature of the solvent; and
c) isolating the Form I of Amlodipine Maleate thus obtained.

### Claim 16 (depends on 16)

The process according to claim 16, wherein the solvent used in step a) is selected from C2-C6 straight or branched ester.

### Claim 17 (depends on 15, 16)

The process according to claim 15 or 16, wherein the C2-C6 straight or branched ester is selected from the group consisting of ethyl acetate, tertiary butyl acetate, methyl acetate, methyl tertiary butyl acetate and n-butyl acetate.

### Claim 18 (depends on 15, 16, 17)

The process according to claim 15, 16 or 17, wherein the single solvent used is tertiary butyl acetate.

### Claim 19 (depends on 15)

The process according to claim 15, wherein the mixture of solvents used in step a) is selected from the group consisting of n-butanol and methyl tertiary butyl ether; toluene and isopropyl alcohol; tertiary butanol and cyclohexane or tetrahydrofuran; and n-butanol, dioxane, n-propylacetate, toluene, diusopropylether, or cyclohexane and tertiary butyl acetate.

### Claim 20 (depends on 15, 19)

The process according to claims 15 or 19, wherein the mixture of solvents used is n-butanol and methyl tertiary butyl ether.

### Claim 21 (depends on 15, 19, 20)

The process according to claim 15, 19 or 20, wherein the ratio of a more polar solvent to a less polar solvent used in the mixture of solvents is 1:1 to 10 v/v.

### Claim 22 (depends on 21)

The process according to claim 21, wherein the ratio of more polar solvent to the less polar solvent used in the mixture of solvents is 1:1 to 5 v/v.

### Claim 23 (depends on 21)

The process according to claim 21, wherein the ratio of more polar solvent to the less polar solvent used in the mixture of solvents is 1:1 v/v.

### Claim 24

A process for the preparation of Form II of Amlodipine maleate, which comprises the steps of:
a) dissolving maleic acid in a mixture of solvents followed by addition of Amlodipine base;
b) maintaining the reaction mixture of step a) at a temperature ranging from ambient to the reflux temperature of the solvent; and
c) isolating Form II of Amlodipine Maleate thus obtained.

### Claim 25 (depends on 24)

The process according to claim 24, wherein mixture of solvents used in step a), is selected from the group consisting of: n-propanol and diethylether; ethyl acetate and toluene; methyl isobutyl ketone and tertiary butyl acetate; and tertiary butanol and diisopropylether.

### Claim 26 (depends on 25)

The process according to claim 25, wherein the mixture of solvents used is n-propanol and diethylether.

### Claim 27 (depends on 24, 25, 26)

The process according to claim 24, 25 or 26, wherein the ratio of a more polar solvent to the less polar solvent used in the mixture of solvents is 1:1 to 10 v/v.

### Claim 28 (depends on 27)

The process according to claim 27, wherein the ratio of a more polar solvent to the less polar solvent used in the mixture of solvents is 1:1 to 5 v/v.

### Claim 29 (depends on 27)

The process according to claim 27, wherein the ratio of more polar solvent to the less polar solvent used in the mixture of solvents is 1:1 v/v.

### Claim 30

A pharmaceutical formulation comprising as an active ingredient, Form I of Amlodipine maleate and a pharmaceutically acceptable carrier, excipient or diluent; wherein said Form I of Amlodipine maleate is characterized by an XRD pattern with 2θ values at about 4.459, 8.871, 10.593, 11.160, 11.488, 12.700, 13.296, 13.590, 15.694, 17.730, 18.156, 18.608, 19.208, 19.772, 20.126, 20.908, 21.523, 21.964, 22.985, 23.687, 24.584, 25.085, 25.538, 26.269, 26.753, 27.504, 28.095, 29.972, 30.433, 31.175, 31.824, 32.671, 33.564, 34.132, 36.223, 37.836, 38.776, 39.914.

### Claim 31

A pharmaceutical formulation comprising as an active ingredient, Form II of Amlodipine maleate and a pharmaceutically acceptable carrier, excipient or diluent; wherein said Form II of Amlodipine maleate is characterized by an X-ray powder diffraction pattern with 2θ values at about 4.421, 8.851, 10.147, 11.421, 12.032, 12.644, 13.071, 13.297, 13.490, 14.435, 14.838, 15.655, 17.052, 17.561, 18.072, 18.611, 19.186, 19.692, 20.078, 21.237, 21.958, 22.912, 23.536, 24.191, 24.493, 25.058, 25.932, 26.264, 26.717, 27.250, 28.051, 29.778, 31.728, 33.512, 33.987, 35.233, 37.085, 40.536.

### Claim 32

A pharmaceutical formulation comprising Form I of Amlodipine maleate, Form II of Amlodipine maleate and a pharmaceutically acceptable carrier, excipient or diluent; wherein said Form I of Amlodipine maleate is characterized by an XRD pattern with 2θ values at about 4.459, 8.871, 10.593, 11.160, 11.488, 12.700, 13.296, 13.590, 15.694, 17.730, 18.156, 18.608, 19.208, 19.772, 20.126, 20.908, 21.523, 21.964, 22.985, 23.687, 24.584, 25.085, 25.538, 26.269, 26.753, 27.504, 28.095, 29.972, 30.433, 31.175, 31.824, 32.671, 33.564, 34.132, 36.223, 37.836, 38.776, 39.914 and said Form II of Amlodipine maleate is characterized by the X-ray powder diffraction pattern with 2θ values at about 4.421, 8.851, 10.147, 11.421, 12.032, 12.644, 13.071, 13.297, 13.490, 14.435, 14.838, 15.655, 17.052, 17.561, 18.072, 18.611, 19.186, 19.692, 20.078, 21.237, 21.958, 22.912, 23.536, 24.191, 24.493, 25.058, 25.932, 26.264, 26.717, 27.250, 28.051, 29.778, 31.728, 33.512, 33.987, 35.233, 37.085, 40.536.

### Claim 33

A method of treating ischaemia comprising administering an effective amount of Form I of Amlodipine maleate to a patient in need thereof; wherein said Form I of Amlodipine maleate is characterized by an XRD pattern with 2θ values at about 4.459, 8.871, 10.593, 11.160, 11.488, 12.700, 13.296, 13.590, 15.694, 17.730, 18.156, 18.608, 19.208, 19.772, 20.126, 20.908, 21.523, 21.964, 22.985, 23.687, 24.584, 25.085, 25.538, 26.269, 26.753, 27.504, 28.095, 29.972, 30.433, 31.175, 31.824, 32.671, 33.564, 34.132, 36.223, 37.836, 38.776, 39.914.

### Claim 34

A method of treating ischaemia comprising administering an effective amount of Form II of Amlodipine maleate to a patient in need thereof; wherein said Form II of Amlodipine maleate is characterized by an X-ray powder diffraction pattern with 2θ values at about 4.421, 8.851, 10.147, 11.421, 12.032, 12.644, 13.071, 13.297, 13.490, 14.435, 14.838, 15.655, 17.052, 17.561, 18.072, 18.611, 19.186, 19.692, 20.078, 21.237, 21.958, 22.912, 23.536, 24.191, 24.493, 25.058, 25.932, 26.264, 26.717, 27.250, 28.051, 29.778, 31.728, 33.512, 33.987, 35.233, 37.085, 40.536.

### Claim 35

A method of treating hypertension comprising administering an effective amount of Form I of Amlodipine maleate to a patient in need thereof; wherein said Form I of Amlodipine maleate is characterized by an XRD pattern with 2θ values at about 4.459, 8.871, 10.593, 11.160, 11.488, 12.700, 13.296, 13.590, 15.694, 17.730, 18.156, 18.608, 19.208, 19.772, 20.126, 20.908, 21.523, 21.964, 22.985, 23.687, 24.584, 25.085, 25.538, 26.269, 26.753, 27.504, 28.095, 29.972, 30.433, 31.175, 31.824, 32.671, 33.564, 34.132, 36.223, 37.836, 38.776, 39.914.

### Claim 36

A method of treating hypertension comprising administering an effective amount of Form II of Amlodipine maleate to a patient in need thereof; wherein said Form II of Amlodipine maleate is characterized by an X-ray powder diffraction pattern with 2θ values at about 4.421, 8.851, 10.147, 11.421, 12.032, 12.644, 13.071, 13.297, 13.490, 14.435, 14.838, 15.655, 17.052, 17.561, 18.072, 18.611, 19.186, 19.692, 20.078, 21.237, 21.958, 22.912, 23.536, 24.191, 24.493, 25.058, 25.932, 26.264, 26.717, 27.250, 28.051, 29.778, 31.728, 33.512, 33.987, 35.233, 37.085, 40.536.

### Claim 37

A method of preventing ischaemia comprising administering an effective amount of Form I of Amlodipine maleate to a patient in need thereof; wherein said Form I of Amlodipine maleate is characterized by an X-ray powder diffraction pattern with 2θ values at about 4.459, 8.871, 10.593, 11.160, 11.488, 12.700, 13.296, 13.590, 15.694, 17.730, 18.156, 18.608, 19.208, 19.772, 20.126, 20.908, 21.523, 21.964, 22.985, 23.687, 24.584, 25.085, 25.538, 26.269, 26.753, 27.504, 28.095, 29.972, 30.433, 31.175, 31.824, 32.671, 33.564, 34.132, 36.223, 37.836, 38.776, 39.914.

### Claim 38

A method of preventing ischaemia comprising administering an effective amount of Form II of Amlodipine maleate to a patient in need thereof; wherein said Form II of Amlodipine maleate is characterized by an X-ray powder diffraction pattern with 2θ values at about 4.421, 8.851, 10.147, 11.421, 12.032, 12.644, 13.071, 13.297, 13.490, 14.435, 14.838, 15.655, 17.052, 17.561, 18.072, 18.611, 19.186, 19.692, 20.078, 21.237, 21.958, 22.912, 23.536, 24.191, 24.493, 25.058, 25.932, 26.264, 26.717, 27.250, 28.051, 29.778, 31.728, 33.512, 33.987, 35.233, 37.085, 40.536.

### Claim 39

A method of preventing hypertension comprising administering an effective amount of Form I of Amlodipine maleate to a patient in need thereof; wherein said Form I of Amlodipine maleate is characterized by an X-ray powder diffraction pattern with 2θ values at about 4.459, 8.871, 10.593, 11.160, 11.488, 12.700, 13.296, 13.590, 15.694, 17.730, 18.156, 18.608, 19.208, 19.772, 20.126, 20.908, 21.523, 21.964, 22.985, 23.687, 24.584, 25.085, 25.538, 26.269, 26.753, 27.504, 28.095, 29.972, 30.433, 31.175, 31.824, 32.671, 33.564, 34.132, 36.223, 37.836, 38.776, 39.914.

### Claim 40

A method of preventing hypertension comprising administering an effective amount of Form II of Amlodipine maleate to a patient in need thereof; wherein said Form II of Amlodipine maleate is characterized by an X-ray powder diffraction pattern with 20 values at about 4.421, 8.851, 10.147, 11.421, 12.032, 12.644, 13.071, 13.297, 13.490, 14.435, 14.838, 15.655, 17.052, 17.561, 18.072, 18.611, 19.186, 19.692, 20.078, 21.237, 21.958, 22.912, 23.536, 24.191, 24.493, 25.058, 25.932, 26.264, 26.717, 27.250, 28.051, 29.778, 31.728, 33.512, 33.987, 35.233, 37.085, 40.536.
